Sildenafil
Interstitial Lung Disease
University of California, Los AngelesSmall moleculePhase 4 / ApprovedDormant
B
61/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 46/ 100
- Competitive Position
- 89/ 100
Competitive context
17 Active assets in the Interstitial Lung Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Prednisone National Institute for Tuberculosis and Lung Diseases, Poland | Phase 4 | BB |
Uniprost United Therapeutics | Phase 3 | BB |
Cyclophosphamide Intergroupe Francophone de Cancerologie Thoracique | Phase 2/3 | B |
Rituximab Royal Brompton & Harefield NHS Foundation Trust | Phase 2/3 | B |
Bardoxolone Methyl Ester Biogen | Phase 2 | B |
View all 34 →
Same molecule, other indications
Sildenafil is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →